| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2018-09-27 |
Editas Medicine (USA - MA) |
chief medical officer |
|
resignation |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Resignation |
| 2018-09-27 |
Cellular Biomedicine Group (China) Novartis (Switzerland) |
Kymriah® - CTL019 (tisagenlecleucel-T) |
|
manufacturing - production |
Cancer - Oncology - Technology - Services |
Production agreement |
| 2018-09-27 |
Cellular Biomedicine Group (China) Novartis (Switzerland) |
Kymriah® - CTL019 (tisagenlecleucel-T) |
|
manufacturing - production |
Cancer - Oncology - Technology - Services |
Production agreement |
| 2018-09-27 |
Allogene Therapeutics (USA - CA) |
member of the board of directors |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-09-27 |
BioInvent (Sweden) Cardiovax (USA - CA) |
orticumab (BI-204) |
|
production - manufacturing |
Inflammatory diseases - Technology Services |
Production agreement |
| 2018-09-26 |
Celyad (Belgium) |
vice president |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-09-25 |
Cobra Biologics (Sweden) Centre for Process Innovation (CPI) (UK) GE Healthcare Life Sciences (USA - WI) |
manufacturing of adeno-associated virus (AAV) vectors |
|
collaboration |
Technology - Services |
Collaboration agreement |
| 2018-09-25 |
KSQ Therapeutics (USA - MA) |
member of the board of directors |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-09-21 |
InflaRx (Germany) |
member of the board |
|
nomination |
Inflammatory diseases |
Nomination |
| 2018-09-20 |
Celltrion Healthcare (South Korea) Emory University (USA - GA) |
new drug candidates for atherosclerosis |
atherosclerosis |
development |
Cardiovascular diseases |
Development agreement |
| 2018-09-19 |
Abzena (UK) Tmunity Therapeutics (USA - PA) |
- fully-humanized therapeutic antibodies devoid of CD4+ T cell epitopes
|
|
services contract |
Cancer - Oncology - Technology - Services |
Services contract |
| 2018-09-19 |
Poietis (France) Servier (France) |
4D bioprinting of liver tissues |
|
research - development - R&D |
Technology - Services |
Research agreement |
| 2018-09-18 |
Thrombogenics (Belgium) Alcon (USA -TX), a Novartis subsidiary (Switzerland) |
Jetrea® (ocriplasmin) |
symptomatic vitreomacular adhesion |
commercialisation |
Ophtalmological diseases |
Termination of an agreement |
| 2018-09-18 |
Tmunity Therapeutics (USA - PA) |
executive vice-president |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-09-17 |
Respivant Sciences (USA - CA) |
|
|
nomination |
Lung diseases - Respiratory diseases - Rare diseases |
Nomination |
| 2018-09-17 |
Fate Therapeutics (USA - CA) Ono Pharmaceutical (Japan) |
two off-the-shelf CAR-T cell product candidates |
lymphoblastic leukemias, solid tumors |
- development - commercialisation
|
Cancer - Oncology |
Development agreement |
| 2018-09-17 |
Accenture (Ireland) Amazon (USA - CA) Merck&Co (USA - NJ) |
cloud-based informatics research platform |
|
collaboration |
Technology - Services |
Collaboration agreement |
| 2018-09-14 |
Horizon Discovery (UK) AstraZeneca (UK) |
Edit-R™ crRNA libraries |
|
services contract |
Technology - Services |
Services contract |
| 2018-09-13 |
Fate Therapeutics (USA - CA) J. David Gladstone Institutes (USA - CA) |
CRISPR-mediated gene activation |
|
licensing |
Technology - Services |
Licensing agreement |
| 2018-09-13 |
Lysogene (France) |
|
|
resignation |
Rare diseases - Genetic diseases |
Resignation |
